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Abstract
TRIM5a is an antiviral, cytoplasmic, E3 ubiquitin (Ub) ligase that
assembles on incoming retroviral capsids and induces their prema-
ture dissociation. It inhibits reverse transcription of the viral
genome and can also synthesize unanchored polyubiquitin (poly-
Ub) chains to stimulate innate immune responses. Here, we show
that TRIM5a employs the E2 Ub-conjugating enzyme Ube2W to
anchor the Lys63-linked polyUb chains in a process of TRIM5a
auto-ubiquitination. Chain anchoring is initiated, in cells and
in vitro, through Ube2W-catalyzed monoubiquitination of TRIM5a.
This modification serves as a substrate for the elongation of
anchored Lys63-linked polyUb chains, catalyzed by the heterodi-
meric E2 enzyme Ube2N/Ube2V2. Ube2W targets multiple TRIM5a
internal lysines with Ub especially lysines 45 and 50, rather
than modifying the N-terminal amino group, which is instead
aN-acetylated in cells. E2 depletion or Ub mutation inhibits
TRIM5a ubiquitination in cells and restores restricted viral reverse
transcription, but not infection. Our data indicate that the step-
wise formation of anchored Lys63-linked polyUb is a critical early
step in the TRIM5a restriction mechanism and identify the E2
Ub-conjugating cofactors involved.
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Introduction
TRIM5a is an innate immune effector that belongs to the tripartite
(TRIM) protein superfamily. The conserved tripartite architecture
comprises a really interesting new gene (RING) E3 ubiquitin (Ub)
ligase domain, one or two B-box domains, and a coiled-coil,
followed by variable protein interaction domain(s). Although TRIM
proteins can have wide-ranging biological roles, anti-pathogen
defense functions are common (Nisole et al, 2005; McNab et al,
2011). The expression of many TRIM proteins is induced by type I
interferons, and several have been shown to manipulate immune
signaling pathways by ubiquitinating signal transducing proteins,
such as TRIM23, TRIM25, and TRIM56 (Gack et al, 2007; Arimoto
et al, 2010; Tsuchida et al, 2010). Certain TRIM proteins, including
TRIM5a (Stremlau et al, 2004), TRIM21 (Mallery et al, 2010), and
TRIM56 (Wang et al, 2011), have also been shown to target viral
replication specifically. An emerging theme is that antiviral TRIM
proteins both inhibit viral infection and initiate innate immune
signaling cascades that lead to inflammatory cytokine production
and an antiviral state (Pertel et al, 2011; McEwan et al, 2013; Uchil
et al, 2013; Versteeg et al, 2013). The molecular mechanisms that
underlie these multiple activities are not yet well defined and are of
great interest for understanding the innate immune detection of
viruses.
TRIM5a represents an important barrier to zoonotic retroviral
infection (Stremlau et al, 2004; Wu et al, 2013, 2015). Multimers of
homodimeric TRIM5a bind susceptible retroviral capsids in the cyto-
plasm, inducing premature capsid dissociation and inhibiting reverse
transcription (Stremlau et al, 2006; Diaz-Griffero et al, 2009; Black &
Aiken, 2010; Ganser-Pornillos et al, 2011; Zhao et al, 2011;
Goldstone et al, 2014). Several observations indicate the involve-
ment of the Ub-proteasome system in these processes: (i) protea-
some inhibitors restore slow capsid dissociation kinetics and rescue
formation of integration-competent reverse transcripts, but do not
restore viral infectivity (Anderson et al, 2006; Wu et al, 2006;
Kutluay et al, 2013); (ii) TRIM5a and proteasomal components
co-localize in cells (Campbell et al, 2008; Lukic et al, 2011; Danielson
et al, 2012); and (iii) the short half-life of TRIM5a is decreased even
further upon recognition of restriction-sensitive capsids (Rold &
Aiken, 2008), and lengthened by proteasome inhibition (Diaz-Griffero
et al, 2006). Thus, one plausible model for restriction is that
TRIM5a–capsid complexes are diverted into a constitutive, protea-
some-dependent unfolding/degradation pathway (Towers, 2007),
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although an alternative autophagosomal unfolding/degradation
model has also been suggested (Mandell et al, 2014). In addition to
proteasome recruitment, TRIM5a has been shown to generate unan-
chored Lys63-linked polyubiquitin (polyUb) chains upon binding to
susceptible retroviral capsids. These unanchored polyUb chains are
postulated to activate transforming growth factor-b-activated kinase 1
(TAK1), which in turn stimulates NF-jB nuclear translocation and
induces antiviral gene expression (Shi et al, 2008; Pertel et al, 2011).
The Ub enzymology underlying different TRIM5a activities
remains to be defined. Toward this end, we have employed genetic
and biochemical approaches to identify and characterize two E2 Ub-
conjugating enzymes required for TRIM5a restriction of retroviral
reverse transcription: Ube2W and the heterodimeric Ube2N/Ube2V2.
We find that Ube2W can attach single Ub molecules directly to
TRIM5a, which can then act as substrates for Ube2N/Ube2V2 in
the synthesis of TRIM5a-anchored Lys63-linked polyUb chains,
both in vitro and in cells. We find that TRIM5a is aN-acetylated in
cells, a modification that blocks N-terminal ubiquitination, and that
Ube2W targets specific TRIM5a lysine residues with Ub in vitro.
Furthermore, Ube2W, Ube2N/Ube2V2, and the Ub residue Lys63 are
each required for TRIM5a restriction of viral DNA synthesis, but not
infection. Thus, our data indicate that TRIM5a employs multiple E2
enzymes to synthesize protein-anchored Ub chains that are required
for inhibition of retroviral reverse transcription.
Results
TRIM5a requires two non-redundant E2 enzymatic activities to
inhibit retroviral DNA synthesis
We performed an RNAi screen to identify non-redundant E2
Ub-conjugating enzymes required for TRIM5a antiviral activity.
Because proteasome inhibitors restore retroviral reverse transcrip-
tion without rescuing viral infectivity (Anderson et al, 2006; Wu
et al, 2006; Kutluay et al, 2013), we reasoned that abrogating func-
tionally important ubiquitination activities associated with TRIM5a
should rescue reverse transcription, but might not rescue viral infec-
tivity. Human TRIM5a (TRIM5ahu) acts differently on two closely
related variants of murine leukemia virus (MLV) that differ in their
capsid sequences: TRIM5ahu restricts N-tropic MLV (N-MLV) but
not B-tropic MLV (B-MLV) (Towers et al, 2000; Besnier et al, 2003;
Keckesova et al, 2004; Perron et al, 2004; Yap et al, 2004). B-MLV
therefore serves as a convenient control for differentiating between
loss of TRIM5ahu-dependent E2 activities, which should specifically
affect N-MLV infection, versus alterations in cell viability or metabo-
lism, which should affect both N-MLV and B-MLV. We used single-
round, VSV-G-pseudotyped N- and B-MLV vectors expressing GFP
to assess endogenous TRIM5ahu activity. As expected, these two
viral vectors were equally infectious in feline CrFK cells, which do
not express a restricting TRIM5a protein (McEwan et al, 2009)
(Supplementary Fig S1A), but were differentially infectious in
human HeLa cells, which endogenously express TRIM5a (Fig 1A,
Mock). siRNAs targeting 38 different human E2 or E2 variant (UEV)
proteins, which collectively encompass the majority of known
human E2 enzymes (Markson et al, 2009), were then tested for
their ability to restore N-MLV DNA synthesis (Fig 1A). The three
strongest hits were Ube2W, Ube2N (Ubc13), and Ube2V2 (Mms2);
individual depletions of any of these E2 proteins abrogated
TRIM5ahu-dependent restriction of N-MLV DNA synthesis comple-
tely. These three proteins likely represent just two different E2 enzy-
matic activities because Ube2N and Ube2V2 function together in a
heterodimeric E2 enzyme complex comprising an active Ube2N E2
subunit and a catalytically inactive Ube2V2 subunit that provides
specificity for synthesis of Lys63-linked polyUb chains (Hofmann &
Pickart, 1999; McKenna et al, 2003).
The strongest hits from the siRNA screen were validated by indi-
vidually depleting Ube2W, Ube2N, and Ube2V2 from restrictive
human TE671 cells using shRNA stably expressed from retroviral
vectors (Fletcher et al, 2010). E2-depleted cells were infected with
equivalent doses of N- or B-MLV, and viral DNA synthesis and
infectivity were measured 6 and 48 h postinfection, respectively.
Cells expressing a scrambled control shRNA restricted N-MLV effi-
ciently, as measured by strong reductions in DNA synthesis (Fig 1B)
and infectivity (Fig 1C). However, depleting either Ube2W, Ube2N,
or Ube2V2 substantially rescued N-MLV DNA synthesis, without
major effects on unrestricted B-MLV DNA synthesis (Fig 1B). As
predicted, E2 depletion rescued DNA synthesis more effectively than
it rescued viral infectivity, validating the logic of the screen readout
[compare Fig 1C (infection) with B (DNA synthesis)]. Specific deple-
tion was confirmed by RT–qPCR for Ube2W and Ube2V2 (Fig 1D
and Supplementary Fig S1B) or immunoblot (IB) for Ube2N
(Fig 1E). Because Ube2N can function with either Ube2V2 or
Ube2V1 (Uev1a) (Hofmann & Pickart, 1999), we confirmed that
depletion of Ube2V1 did not rescue restricted N-MLV DNA synthesis
in TE671 cells (Supplementary Fig S1C and D). Furthermore, deple-
tion of Ube2V2 had no impact on the expression of either Ube2V1
(Fig 1D) or Ube2N (Fig 1E). These experiments indicate that both
Ube2W and Ube2N/Ube2V2 are required for efficient restriction of
retroviral reverse transcription by TRIM5ahu.
TRIM5a can be ubiquitinated and degraded in a proteasome-
dependent fashion
We next analyzed the ubiquitination state of TRIM5ahu under condi-
tions of proteasome inhibition. We treated TE671 cells exogenously
expressing HA-TRIM5ahu with the proteasome inhibitor MG132, and
HA-TRIM5ahu species were detected by IB against the HA-tag
(Fig 2A). A 2-hour MG132 treatment leads to accumulation of
higher molecular weight (HMW) HA-TRIM5ahu species (Fig 2A, lane
2). The HMW products continued to increase with time, ultimately
becoming the predominant TRIM5a species after 10 h of MG132
treatment (Fig 2A, lane 5). Measurement of the HA band densities
corresponding to the unmodified and HMW forms of HA-TRIM5ahu
demonstrated that it is not the unmodified form that accumulated in
these experiments (Fig 2A); rather it is the HMW species that accu-
mulate, consistent with post-translational modification, such as
ubiquitination. We assume their accumulation reflects a lack of
degradation owing to proteasome inhibition.
To control for non-specific effects of overexpressing a RING
domain-containing protein in cells, we also performed parallel
control experiments on TE671 expressing HA-TRAF6, another RING
E3 ligase involved in innate immune signaling (Xia et al, 2009). In
contrast to TRIM5ahu, only very small amounts of HMW HA-TRAF6
species accumulated upon MG132 treatment, whereas the unmodi-
fied form accumulated (Fig 2B), suggesting that HMW accumulation
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Figure 1. TRIM5a restriction of N-MLV reverse transcription requires the E2 enzymes Ube2W, Ube2N, and Ube2V2.
A siRNA screen against 38 human E2 Ub-conjugating enzymes in HeLa cells identifies three enzymes necessary for the block to N-MLV reverse transcription. HeLa
cells in duplicate 96-well plates were reverse-transfected with siRNA SMARTpools at a final concentration of 30 nM. Cells were washed 24 h post-transfection and
then incubated for additional 24 h. Cells were then infected with either N-tropic or B-tropic MLV-GFP vector expressing GFP at MOI ~0.2. At 6 h post infection (p.i.),
cells were lysed, total DNA was purified, and copies of viral DNA (TaqMan GFP qPCR) were determined and plotted as the ratio of B-MLV:N-MLV copies/100 ng total
DNA. Values are means of triplicate experiments.
B, C TE671 cells that stably expressed Ube2W-, Ube2V2-, or Ube2N-specific shRNA, or a scrambled shRNA (Scr) were transduced with N- or B-MLV-GFP vectors. Copies
of viral DNA at 6 h post infection (p.i.) (TaqMan GFP qPCR) (B) and percent infection at 48 h p.i. (flow cytometry for GFP) (C) were determined in parallel samples.
Boiled virus served as a negative control for plasmid contamination. Mean  SEM, n = 3. See also Supplementary Figure S1.
D mRNA levels of Ube2V2, Ube2V1, or Ube2W were assessed by RT–qPCR in TE671 cells that stably expressed Ube2V2- or Ube2W-specific shRNA or Scr. Values were
calculated relative to GAPDH mRNA and expressed relative to levels in cells expressing Scr control. Mean  SEM of triplicates.
E Immunoblot (IB) detecting Ube2N in two cell lines expressing Ube2V2-specific shRNA (V2c1 and V2c2) or cells expressing Ube2N-specific shRNA.
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is not a general property of overexpressing an active RING E3 ligase.
Our observations are consistent with a model in which TRIM5ahu is
post-translationally modified, leading to accumulation of HMW
species that are normally turned over in a proteasome-dependent
fashion. This result should be treated with some caution, however,
because proteasome inhibition, and consequent Ub depletion, can
also affect other Ub-dependent cellular processes.
To confirm that the HMW TRIM5ahu species were ubiquitination
products, we co-transfected 293T cells with 6×His-tagged TRIM5ahu
(His-TRIM5ahu) and HA-tagged Ub (HA-Ub). His-TRIM5ahu species
were enriched by Ni2+ affinity purification, and the HMW His-
TRIM5ahu species were confirmed as ubiquitinated products by IB,
detecting the HA-tag (Fig 2C, lanes 4 and 6). Importantly, in this
case, ubiquitinated His-TRIM5ahu species were detectable in the
absence of MG132 treatment (lane 4). We assume that these species
were enriched by the affinity purification step and could therefore
be detected by IB. Ubiquitinated TRIM5ahu ((Ub)n-TRIM5a) was
also detected in a reciprocal affinity purification (pulldown of
His-Ub, IB detection of HA-TRIM5ahu), again in the absence of
MG132 treatment (Fig 2D). These experiments demonstrate that
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Figure 2. Constitutively ubiquitinated TRIM5a is a proteasome substrate.
A, B Proteasome inhibition reveals TRIM5ahu high molecular weight (HMW) species. TE671 cells that expressed HA-TRIM5ahu (A) or a control RING protein, HA-TRAF6
(B), were treated with the proteasome inhibitor MG132, lysed at the indicated time intervals, and analyzed by IB detection of the HA-tag (HA), or b-actin (loading
control). The band intensity ratios (ImageJ) (HA:b-actin) of unmodified HA-TRIM5ahu (labeled “1”) and HMW HA-TRIM5ahu (labeled “2”) are displayed beneath and
normalized to the 0-h time point and plotted.
C, D Constitutive TRIM5ahu autoubiquitination can also be detected in the absence of MG132. 293T cells were transfected with the designated combinations of
expression constructs for 6×His-TRIM5ahu and HA-Ub. After 48 h, 6×His-TRIM5ahu was pulled down (PD) with a Ni
2+ affinity matrix, followed by analysis of the
input and affinity-purified samples by IB with the designated antibodies (C). TE671 cells that stably expressed HA-TRIM5ahu were mock-transfected or transfected
with a construct expressing 6×His-Ub. Cells were not treated with MG132. After 48 h, 6×His-Ub was affinity-purified and the samples were analyzed by IB (D).
Antibodies were against the HA-tag (HA), the His-tag (His), or b-actin (loading control). Note some unmodified TRIM5ahu precipitates with the Ni
2+ affinity matrix
in a 6×His-Ub-independent manner.
Data information: All blots are representative of at least three independent experiments.
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TRIM5a can be heavily ubiquitinated in cells, in good agreement
with some previous studies (Diaz-Griffero et al, 2006), but not
others (Rold & Aiken, 2008).
Depletion of Ube2W or Ube2N/Ube2V2 suppresses TRIM5a
ubiquitination in cells
We next tested whether the E2 enzymes required for TRIM5ahu
restriction of N-MLV DNA synthesis also participate in TRIM5ahu
ubiquitination. As shown in Fig 3, single depletions of Ube2W,
Ube2N, or Ube2V2 each strongly inhibited the formation of HMW
TRIM5ahu Ub adducts that otherwise accumulated upon proteasome
inhibition. However, the resulting distributions of TRIM5ahu species
varied in the different cases. Ube2W depletion abrogated all detect-
able TRIM5ahu ubiquitination (Fig 3A), whereas depletion of either
Ube2N or Ube2V2 prevented polyUb chain formation but did not
prevent formation of a monoubiquitin (monoUb) TRIM5ahu species
(Ub-TRIM5ahu, Fig 3B and C). The similar accumulation of Ub-
TRIM5ahu following depletion of either Ube2N or Ube2V2 is consis-
tent with the idea that these two E2 activities function together as a
single Ub E2 conjugating enzyme. Together, our observations are
consistent with a model in which Ube2W mediates TRIM5a mono-
ubiquitination and the Ube2N/Ube2V2 enzyme then extends the
polyUb chain from the anchoring Ub.
TRIM5a is modified with Lys63-linked polyUb chains in cells
The observations that HMW TRIM5ahu species accumulate in the
absence of proteasome activity and that depletion of either Ube2W
or Ube2N/Ube2V2 blocks this accumulation were surprising
because proteasome recruitment and protein degradation are typi-
cally mediated by Lys48 (K48)-linked polyUb chains, whereas
Ube2W typically modifies proteins with monoUb and the Ube2N/
Ube2V2 heterodimer typically builds Lys63-linked polyUb chains
(K63-Ub) (VanDemark et al, 2001; Christensen et al, 2007; Scaglione
et al, 2013; Tatham et al, 2013). We therefore characterized the
nature of the polyUb linkages within the TRIM5ahu HMW species by
co-expressing and purifying mutant Ub proteins that either could
not form K63-Ub (Ub K63R) or could not form K48-linked chains
(Ub K48R). As shown in Fig 4A, formation of (Ub)n-TRIM5ahu
species was normal after expression of Ub K48R, but was efficiently
blocked by expression of Ub K63R, consistent with the idea that
Ube2N/Ube2V2 catalyzes formation of K63-Ub on TRIM5ahu
(Fig 4A). Importantly, Ub K63R species were present at normal
levels in cell lysates as verified by detecting the 6×His tag (Fig 4A,
panel 2). The Ub K63R-mediated suppression of TRIM5ahu HMW
species was as efficient as the suppression seen upon depletion of
Ube2N (Fig 4B). These observations suggest that TRIM5a is specifi-
cally labeled with K63-Ub by Ube2N/Ube2V2. In further support of
this hypothesis, an antibody specific for K63-linked Ub chains
reacted well with affinity-purified His-TRIM5ahu HMW species
(Fig 4C). In this case, K63-linked (Ub)n-TRIM5ahu species were
detected in the absence of exogenous Ub expression (Fig 4C, lane 3)
and were even more prevalent upon Ub overexpression (Fig 4C,
lane 4). Thus, the (Ub)n-TRIM5ahu species contain K63 linkages.
To test the functional importance of K63-linked polyUb modifi-
cation of TRIM5a for restriction, we overexpressed Ub K63R in
TE671 cells and assayed restriction of N-MLV DNA synthesis.
Like Ube2N depletion (Fig 1), Ub K63R overexpression restored
restricted N-MLV DNA synthesis to nearly the same level as the
unrestricted B-MLV control (Fig 4D). Once again, viral infectivity
was not substantially restored (Fig 4E), as measured in a luciferase-
based infectivity assay. Together, these results indicate that
Ube2N/Ube2V2 adds K63-linked polyUb chains to TRIM5a and that
these modifications are required for restriction of N-MLV DNA
synthesis.
The N-terminus of TRIM5a is quantitatively acetylated in cells
Ube2W has been shown to catalyze formation of a conventional
peptide bond between the C-terminus of Ub and the free N-terminus
of several proteins in vitro (Scaglione et al, 2013; Tatham et al,
2013; Vittal et al, 2015). However, most eukaryotic proteins are co-
translationally acetylated at their N-termini (aN-acetylation), often
following removal of the initiator methionine (Van Damme et al,
2011). aN-acetylation should block N-terminal ubiquitination
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Figure 3. Depletion of Ube2W, Ube2N, or Ube2V2 suppresses TRIM5a
ubiquitination.
A–C TE671 cells stably expressing HA-TRIM5ahu and shRNAs targeting Ube2W
(A), Ube2N (B) or Ube2V2 (C) or a scrambled control shRNA (Scr), or no
shRNA (None), were treated with MG132 for the designated time
intervals, and cell lysates were analyzed by IB detection of HA-TRIM5ahu
(HA), or b-actin (loading control). All blots are representative of at least
three independent experiments.
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because the resulting amide nitrogen is no longer nucleophilic. The
TRIM5a N-terminal sequence, (M)ASGIL, should be a good
substrate for aN-acetylation (Polevoda & Sherman, 2003), and
TRIM5a aN-acetylation has been reported previously (Bienvenut
et al, 2012). We confirmed this observation by analyzing C-termi-
nally FLAG-One-Strep (FOS)-tagged human or rhesus macaque (rh)
TRIM5a proteins expressed in human 293T cells. The exogenously
expressed TRIM5a-FOS proteins were purified by Strep–Tactin affin-
ity chromatography, separated by SDS–PAGE, and digested with
trypsin, and the tryptic peptides were analyzed by liquid chromato-
graphy coupled with tandem mass spectrometry (LC/MS/MS). In
both constructs, we identified N-terminal peptides that lacked the
terminal methionine and were acetylated on the penultimate Ala
residue, whereas non-acetylated or methionylated peptides were not
detected in either case (Supplementary Fig S2A for human and
Supplementary Fig S2B for rhesus). Hence, human and rhesus
TRIM5a proteins are N-terminally acetylated in human cells, which
raises the question of how they might be monoubiquitinated by
Ube2W.
Ube2W monoubiquitinates full-length TRIM5a in vitro
To characterize how Ube2W and Ube2N/Ube2V2 can function
together with TRIM5a, we tested their activities in reconstituted
systems using pure recombinant proteins. These experiments
employed full-length rhesus TRIM5a proteins (TRIM5arh), which
are expected to utilize the same set of functionally important Ub E2
enzymes as TRIM5ahu proteins because TRIM5arh efficiently
restricts retroviral DNA synthesis when expressed in human cells
(Stremlau et al, 2004). The C-terminally tagged TRIM5arh-FOS was
expressed in insect cells, purified by Strep–Tactin affinity chroma-
tography, treated with precision protease to remove the FOS tag,
and purified to homogeneity by gel filtration chromatography.
Electrospray mass spectrometric analysis of the intact purified
recombinant TRIM5arh protein indicated that demethionylation and
aN-acetylation were complete because species representing meth-
ionylated or demethionylated and non-acetylated forms of TRIM5arh
were not detected (Supplementary Fig S3). These data indicate that
our recombinant TRIM5arh protein had the same N-terminal
sequence and modification pattern as TRIM5a proteins expressed in
human 293T cells. Ub (Pickart & Raasi, 2005), E1 (UBA1), and E2
enzymes were all expressed in E. coli and purified to homogeneity
for use in the in vitro ubiquitination assays, see Materials and
Methods section.
To assay Ub ligase activity, TRIM5arh was incubated with
UBA1, Ub, and ATP, together with the different E2 enzymes that
were identified in our cellular assays (Ube2W or Ube2N/Ube2V2
or the closely related Ube2N/Ube2V1), or with one of five different
control E2 enzymes (Ube2B, Ube2C, Ube2H, Ube2L3, or Ube2D3).
We verified that each purified E2 was active and efficiently
charged with Ub by UBA1 (Supplementary Fig S4). TRIM5arh-
dependent Ub ligase activity was monitored by IB, with an anti-Ub
antibody used to detect formation of both unanchored and
TRIM5arh-anchored ubiquitination products (Fig 5A), and an anti-
TRIM5arh antibody used to monitor formation of TRIM5arh-
anchored ubiquitination products alone (Fig 5B). Ube2D3 was used
as a positive control in these experiments because this E2 enzyme
is highly promiscuous and has previously been shown to be capa-
ble of ubiquitinating TRIM5arh in vitro (Yamauchi et al, 2008; Kim
et al, 2011). As expected, Ube2D3 catalyzed the formation of
TRIM5arh-linked polyUb chains, and possibly also unanchored
chains (Fig 5A and B, lane 9). However, Ube2D3 lacked chain
linkage specificity, because individual Ub lysine mutations could
not perturb TRIM5arh autoubiquitination (Supplementary Fig S5A
and Table 1). Moreover, Ube2D3 does not function in TRIM5a
restriction because its efficient depletion did not significantly abro-
gate TRIM5a restriction of N-MLV DNA synthesis or infectivity
(Supplementary Fig S5B–D).
As shown in Fig 5, the closely related Ube2N/Ube2V1 and
Ube2N/Ube2V2 E2 enzymes could collaborate with TRIM5arh to
synthesize polyUb chains (Fig 5A, lanes 6 and 7) that were not
covalently anchored to TRIM5arh (Fig 5B, lanes 6 and 7). This
observation agrees well with a previous report that Ube2N/Ube2V1
and TRIM5arh synthesize unanchored K63-Ub (Pertel et al, 2011).
Ube2W was the only other assayed E2 that exhibited any observable
enzymatic activity (Fig 5, lane 5). In this case, however, the enzyme
predominantly attached a single Ub molecule directly onto
TRIM5arh, and also made a small amount of TRIM5arh with two
attached Ub molecules (Fig 5B, lane 5). The ability of Ube2W to
transfer a single Ub onto TRIM5arh in vitro is consistent with the
pattern of ubiquitination seen in cells, where depletion of Ube2N/
Ube2V2 activity led to accumulation of Ub-TRIM5ahu (Fig 3B and C)
and depletion of Ube2W blocked all detectable TRIM5ahu ubiquiti-
nation (Fig 3A). Thus, Ube2W can catalyze the addition of a single
Figure 4. The polyUb chains on TRIM5a contain Lys63 linkages, and Lys63-linked polyUb chain formation is necessary for restriction of N-MLV DNA synthesis.
A (Ub)n-TRIM5ahu synthesis is inhibited by expression of K63R but not K48R mutant Ub. IB of PD products on Ni
2+ affinity matrices from lysates of TE671 cells
expressing HA-TRIM5ahu transfected with empty vector or 6×His-tagged Ub WT, Ub K48R, or Ub K63R. TRIM5ahu species were detected by IB for the HA-tag (HA),
and equivalent purifications of His-labeled ubiquitinated proteins for each Ub variant were confirmed by IB detection of the 6×His tag (His). Input fractions were
analyzed to confirm that similar levels of TRIM5ahu were present before purification.
B Ube2N depletion prevents accumulation of HMW (Ub)n-TRIM5a species. IB of PD products on Ni
2+ affinity matrices from lysates of TE671 cells expressing HA-
TRIM5ahu and the designated combinations of 6×His-Ub and a Ube2N-specific shRNA. Note that some unmodified TRIM5ahu associated non-specifically with the
Ni2+ affinity matrix in all cases.
C Affinity-purified (Ub)n-TRIM5ahu contains Lys63 linkages. IB of PD products from lysates of 293T cells expressing the designated combinations of 6×His-TRIM5ahu
and HA-Ub. Ubiquitinated products were detected with an antibody specific for Lys63-linked Ub chains (denoted K63-Ub). Input levels of 6×His-TRIM5ahu (His) and
b-actin (loading control) are shown below. Asterisk denotes a non-specific band in the input fraction.
D, E K63R mutant Ub expression rescues TRIM5a-restricted N-MLV DNA synthesis but not infectivity. TE671 cells that stably expressed WT or K63R 6×His-Ub-GFP, or
parental TE671 cells, were transduced with either N- or B-MLV-Luc vectors (MOI ~0.2). Copies of viral DNA at 6 h p.i. (TaqMan luciferase qPCR) (D) and relative
infection at 48 h p.i. [luciferase readout, relative light units relative to calibrated light standard (Promega) (RLU)] (E) were determined in parallel samples and are
plotted as read by the luminometer (GloMax, Promega) without manipulation. Boiled virus served as a negative control. Mean  SEM of triplicates.
Data information: All blots are representative of at least three independent experiments.
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Ub onto TRIM5a in cells, and this activity can be recapitulated
in vitro using pure recombinant proteins.
Ube2N/Ube2V2 builds Lys63 polyUb chains on Ub-TRIM5a in vitro
Previous studies have shown that Ube2N/Ube2V2 and Ube2N/
Ube2V1 can extend a polyUb chain from an anchored Ub that
is attached to a substrate by a different E2, such as Ube2W
(Christensen et al, 2007; Tatham et al, 2013). We therefore tested
whether Ube2N-containing enzymes could use Ub-TRIM5arh
proteins as substrates for further ubiquitination. Ub-TRIM5arh
proteins were created in situ by incubating Ube2W with TRIM5arh
(Fig 6A, lane 2), and a panel of six different E2 enzymes was
tested for the ability to use these Ub-TRIM5arh proteins as
substrates to create TRIM5arh-anchored polyUb chains (Fig 6A
lanes 3–8). Ube2N/Ube2V2 and Ube2N/Ube2V1 enzymes both
exhibited this activity (Fig 6A, lanes 6 and 7, respectively)—note
significant depletion of the band representing Ub-TRIM5arh with
concomitant appearance of TRIM5arh-anchored polyUb—whereas
none of the control E2 enzymes tested showed any observable
activity (Fig 6A, lanes 3–5 and 8). As expected, the TRIM5arh-
linked polyUb chains synthesized by Ube2N/Ube2V2 contained
K63 linkages, as analyzed both by testing the activities of single
K/R Ub mutants (Fig 6B) and by trypsin digestion/mass spectro-
metry mapping experiments (Table 1). Furthermore, we observed
a noticeable difference in the pattern of TRIM5arh polyUb products
produced by Ube2N/Ube2V2 in the presence versus absence of
Ube2W (Supplementary Fig S6A, compare lane 3 to lane 4). In the
absence of Ube2W, darker staining of the IB was observed in a
region representing very high MW polyUb products, which likely
represent longer chains. In contrast, the presence of Ube2W led to
more intense staining over a broader region of the IB, indicating
an overall increase in the number of Ub linkages. This overall
increase was confirmed by quantifying the overall staining inten-
sity of ubiquitination products (lane 3 intensity was 354, lane 4
intensity was 954). The increase in K63 linkages was also
supported by an eight-fold increase in mass spectrometric spectral
counts (Table 1).
Collectively, these results are again in excellent agreement with
the patterns of TRIM5a ubiquitination seen in cells, where Ube2N/
Ube2V2 adds K63-Ub, but can only do this when Ube2W is present
(Figs 1 and 3). We therefore conclude that Ube2W and Ube2N/
Ube2V2 can modify TRIM5a in a sequential reaction in which
Ube2W first adds a single Ub molecule, and Ube2N/Ube2V2 then
builds K63-Ub onto the anchoring Ub molecules.
Ube2W transfers ubiquitin on to internal TRIM5a lysine residues
Mass spectrometric analyses were performed to map the site(s) of
TRIM5arh autoubiquitination. In this case, the Ube2W/TRIM5arh
ubiquitination reaction was performed on a preparative scale to
drive the reaction to completion and to produce sufficient quantities
of products for analysis. Mono- and di-ubiquitinated TRIM5arh prod-
ucts were purified by SDS–PAGE (Supplementary Fig S7A, lanes 4
and 5), and digested with trypsin, and ubiquitinated tryptic peptides
were then identified by LC/MS/MS based upon the presence of
remnant isopeptide-linked Gly-Gly dipeptides (Peng et al, 2003;
Flick et al, 2004). This analysis identified sites of TRIM5arh ubiquiti-
nation on Lys residues 45 and 50 (Supplementary Fig S7B; D.E.
Christensen, C. Nelson, W.I. Sundquist, unpublished observations).
Lys45 and Lys50 are located within the RING domain, near the
expected Ube2W binding site. As expected, peptides corresponding
to the acetylated protein N-terminus were detected, and no other
free or modified N-terminal peptides were detected. A peptide corre-
sponding to K48-linked diUb was also detected in these reaction
mixtures, but this product may arise owing to the high levels of
ubiquitinating enzymes used in this preparative reaction because
this product was not detected in other Ube2W ubiquitination reac-
tions where lower enzyme levels were used (see Table 1).
The observation that Ube2W could add isopeptide-linked
monoUb modifications to internal TRIM5arh Lys residues was
noteworthy because Ube2W has previously been reported to pref-
erentially couple Ub to the free aN-termini of proteins via
conventional peptide bonds (Scaglione et al, 2013; Tatham et al,
2013). We therefore tested the idea that the TRIM5arh aN-acetyl
group was blocking Ube2W-mediated N-terminal ubiquitination,
using a different recombinant TRIM5arh protein that had a free,
unacetylated N-terminus (denoted *TRIM5arh). *TRIM5arh was
obtained by expressing an N-terminally tagged FOS-TRIM5arh
protein in insect cells, purifying the protein by Strep–Tactin affin-
ity chromatography, and removing the N-terminal affinity tag
with PreScission protease to produce a protein with a free
aN-terminus on the resulting non-native, N-terminal Gly-Pro
extension. Ube2W added 1–3 Ub molecules onto *TRIM5arh in
preparative in vitro ubiquitination assays, and in this case, the
di-ubiquitinated products were the most prevalent species
(Supplementary Fig S7A, lanes 2 and 3). Thus, Ube2W added
approximately one additional Ub molecule to the non-acetylated
*TRIM5arh protein than to the acetylated TRIM5arh protein. In
this case, mass spectroscopic mapping experiments detected
peptides that corresponded to aN-terminal ubiquitination
products, as well as isopeptide-linked Ub molecules at internal
Lys residues 45, 50, and less frequently to Lys residues 85, 218,
284, and 372 (see Supplementary Fig S7B, caption). These experi-
ments demonstrate that Ube2W can conjugate Ub to the free
N-terminus of the artificial *TRIM5arh construct. However, when
Table 1. TRIM5arh polyUb chain linkages produced with different E2
enzymes.
E2: None Ube2W Ube2N/V2
Ube2N/
V2 + Ube2W Ube2D3
Lys6 NP NP NP NP NP
Lys11 NP NP NP NP 320,000
Lys27 NP NP NP NP NP
Lys29 NP NP NP NP NP
Lys33 NP NP NP NP NP
Lys48 NP NP NP NP 180,000
Lys63 NP NP 8,000 60,000 92,000
Met1 NP NP NP NP NP
TRIM5arh ubiquitination products were produced in the reactions shown in
Supplementary Fig S6. Ub chain linkages were then determined by tryptic
digestions of the reaction mixtures and LC/MS/MS analyses of the resulting
peptides. Values represent spectral counts for any diagnostic peptides
detected. The absence of diagnostic peptides is denoted NP (not present).
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the N-terminus is blocked by acetylation, as is the case in cells,
Ub can instead be linked to internal Lys residues.
To validate the identity of the TRIM5arh Lys residues ubiquitinated
in the in vitro assay, we prepared mutant TRIM5arh protein with
lysine to arginine substitutions at the two major sites of ubiquitina-
tion located in the RING domain (Lys45, Lys50) and at the adjacent
Lys44 (TRIM5arh3KR). TRIM5arh3KR displayed only a weak ability
to accept Ub from Ube2W (Fig 7A, compare lanes 2 and 6). More-
over, the HMW TRIM5arh smear produced by incubation with
Ube2W and Ube2N/Ube2V2 was much lighter for the TRIM5arh
mutant presumably because there is less monoubiquitinated
TRIM5arh to act as a substrate for polyubiquitination (Fig 7A,
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Figure 5. Ube2W monoubiquitnates TRIM5a in vitro.
A, B In vitro TRIM5arh ubiquitination reaction products analyzed by IB detection using anti-Ub (A) and anti-TRIM5arh (B) antibodies. Reactions were carried out in the
presence of purified recombinant UBA1 (0.2 lM), Ub (10 lM), TRIM5arh (0.4 lM), ATP (5 mM), and the designated E2 enzyme (0.4 lM). After ATP addition, reactions
were incubated for 30 min at 37°C. Reactions were stopped by addition of 2× SDS sample buffer containing 2-mercaptoethanol as a reducing agent. Unanchored
polyubiquitin (polyUb) chains are indicated by an asterisk. See also Supplementary Fig S6. All blots are representative of at least three independent experiments.
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compare lanes 4 and 8). Although the K44R, K45R, and K50R
mutations are found within the RING domain which is responsible
for E2 binding, detection of Ub on the IB revealed that both
TRIM5arh mutants produced unanchored HMW Ub species on incu-
bation with Ube2N/Ube2V2 at similar levels to WT TRIM5arh,
suggesting the mutations did not negatively affect E2 binding
(Fig 7B, compare lanes 3, 7, and 11). Therefore, while mutation of
target lysine residues reduces the specific auto-ubiquitination of
TRIM5arh in vitro, it does not prevent formation of Ub chains.
Furthermore, these results confirm our observation that TRIM5arh
residues Lys45 and Lys50 are the primary sites of Ub attachment
by Ube2W in vitro and that other Lys residues are only weakly
ubiquitinated by Ube2W, as evidenced by the weak band
corresponding to mono-ubiquitination of TRIM5arh3KR (which is
then lost on addition of Ube2N/Ube2V2). Interestingly, Ube2W
appears to enhance the polyubiquitination activity of Ube2N/
Ube2V2 in a TRIM5arh-dependent manner (Fig 7B, compare lanes
4, 8, 12, and 14). This enhanced polyubiquitination activity by
Ube2W is likely the result of aberrant transfer of Ub to the Ube2W
N-terminus or lysines, as is observed in the E2 charging assay
(Supplementary Fig S4B, lane 2, band ‡), which can then function
as the anchoring Ub for polyUb synthesis by Ube2N/Ube2V2.
We then asked whether mutation at these specific lysine residues
was able to similarly diminish TRIM5a ubiquitination in cells. As
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Figure 6. Ube2N-containing E2 enzymes build anchored Lys63-linked polyUb chains on Ub-TRIM5a.
A TRIM5arh ubiquitination reactions used the same conditions as those shown in Fig 5, but with multiple E2 enzymes. Ube2W (lanes 2–8) was used to attach anchoring
monoUb molecules to TRIM5arh in situ, and the indicated E2 enzymes were tested for polyUb chain elongation from the anchored Ub of Ub-TRIM5arh.
B Mutant Ub proteins with the designated Lys to Arg mutations were used to identify the residue(s) used for polyUb chain extension. K0 Ub has all seven lysine
residues mutated to arginine.
Data information: IBs are representative of three experiments. See also Supplementary Fig S6.
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before, we used TRIM5ahu restriction assays to readout restriction
of infection and viral DNA synthesis as a measure of ubiquitination
and proteasome recruitment. We prepared a TRIM5ahu mutant
construct (TRIM5ahu3KR), with an authentic N-terminus, bearing
lysine to arginine substitutions at positions 44, 45, and 50 and tested
its ability to restrict N-MLV infection and DNA synthesis upon
expression in feline CRFK cells. Interestingly, TRIM5ahu3KR was
able to restrict N-MLV DNA synthesis and infection as effectively as
WT TRIM5ahu (Supplementary Fig S8A and B). Treatment of
TRIM5ahu-expressing CrFK cells with MG132 also revealed robust
HMW modification of the TRIM5ahu mutant (Supplementary
Fig S8C), suggesting that additional TRIM5a lysine residues are able
to accept Ub in cells. In support of this, we could specifically purify
ubiquitinated species of TRIM5ahu3KR from cells, at levels compara-
ble to WT protein (Supplementary Fig S8D). Therefore, mutation of
these three lysine residues was unable to preclude TRIM5ahu ubiqui-
tination in cells, suggesting that ubiquitination of TRIM5hu at posi-
tions additional to these is able to support TRIM5a-mediated
inhibition of viral replication in cells.
We therefore examined a second pair of TRIM5a mutants.
TRIM5arh8KR (K44R, K45R, K50R, K85R, K218R, K284R, K371R,
K372R) is mutated at all of the Lys residues found to be ubiquitin-
ated by MS analysis as well as at lysine residues 44 and 371,
selected for mutation based on close proximity to lysine residues 45
and 372. In vitro, TRIM5arh8KR was very substantially impaired in
auto-ubiquitination with Ube2W (Fig 7A, compare lanes 2 and 10,
and 4 and 12). Importantly, as for the WT protein, the small amount
of monoubiquitination seen on TRIM5arh8KR (Fig 7A, lanes 9 and
10) was lost on addition of Ube2N/Ube2V2 and converted a faint
HMW smear, consistent with polyubiquitination of the small
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Figure 7. Mutation of Lys45 and Lys50 blocks TRIM5a auto-ubiquitination in vitro.
A, B In vitro TRIM5arh ubiquitination reaction products analyzed by IB detection using anti-TRIM5arh (A) and anti-Ub (B) antibodies and the same conditions as those
shown in Fig 5 but with TRIM5arh lysines mutated to arginine (3KR: K44R, K45R, K50R and 8KR: K44R, K45R, K50R, K85R, K218R, K284R, K371R, K372R; Lys44 and
Lys371 were selected based on close proximity to Lys45 and Lys372). All blots are representative of at least three independent experiments.
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amount of monoubiquitinated TRIM5arh8KR. We also prepared an
equivalent mutant in TRIM5ahu (TRIM5ahu7KR). This protein has
lysine to arginine substitutions at positions 44, 45, 50, 84, 282, 367,
368. Note that TRIM5arh K218 is not conserved in the human ortho-
logue, and TRIM5arh K85, K284, K371, and K372 are equivalent to
TRIM5ahu residues K84, K282, K367, and K368, respectively. We
did not expect TRIM5ahu7KR to restrict infection when expressed in
cells because TRIM5ahu residues Lys367 and Lys368 are located in
the surface-exposed PRYSPRY loop 5 (Supplementary Fig S8E) (Biris
et al, 2012), and their simultaneous mutation can impair restriction
activity by decreasing binding to N-MLV capsid protein (Sebastian
et al, 2009). Consistent with this expectation, TRIM5ahu7KR was
unable to restrict either N-MLV DNA synthesis or infection (Supple-
mentary Fig S8A and B). However, TRIM5ahu7KR still produced
HMW species upon MG132 treatment (Supplementary Fig S8C).
Similarly, ubiquitinated TRIM5ahu7KR species could be purified
from cells, at levels similar to WT protein, even in the absence of
proteasome inhibitor (Supplementary Fig S8D). We conclude that
TRIM5ahu7KR is probably inactive owing to mutations in the
PRYSPRY domain. Nevertheless, this mutant reveals that even when
all of the identified in vitro ubiquitination sites are mutated,
TRIM5ahu7KR can be ubiquitinated at additional sites in cells.
Discussion
In this study, we demonstrate that the anti-retroviral restriction
factor TRIM5a is labeled with Ub in cells in a Ube2W-, Ube2N-,
UbeV2-, and K63-Ub-dependent manner. Depletion of Ube2W abol-
ished all conjugation of Ub to cellular TRIM5a, whereas depletion of
Ube2N or Ube2V2 abolished poly- but not monoubiquitination
(Fig 3). Reconstitution of ubiquitination reactions in vitro using
purified full-length TRIM5a revealed that TRIM5a efficiently cata-
lyzed auto-monoubiquitination using Ube2W (Fig 5) and that this
modification was converted into anchored K63-Ub by addition of
Ube2N/Ube2V2 (Fig 6). Our data add TRIM5a to the growing list of
E3 Ub ligases shown to catalyze Ube2W-dependent monoubiquitina-
tion in vitro (Christensen et al, 2007; Alpi et al, 2008; Scaglione
et al, 2011; Zhang et al, 2011; Tatham et al, 2013; Vittal et al,
2015). The cooperation between Ube2W and Ube2N/Ube2V2 has
also been observed in vitro (Christensen et al, 2007; Tatham et al,
2013). To the best of our knowledge, however, TRIM5a represents
the first instance in which the sequential ubiquitination mechanism
has been dissected in cells using assays for protein function.
In experiments where the relevant E2 enzyme was depleted, or
Ub K63R was expressed, we observed that TRIM5a ubiquitination
activity correlated with its restriction of retroviral DNA synthesis by
reverse transcription, but not with its inhibition of viral infection.
Interestingly, inhibition of proteasomes with small molecules
(Anderson et al, 2006; Wu et al, 2013) also rescues restricted
reverse transcription but not infection. Our data therefore suggest
that the role of TRIM5a ubiquitination is not to prevent viral infec-
tion per se, but to block viral reverse transcription, through a mech-
anism that also requires proteasome activity. This model is
consistent with those in which viral infectivity is suppressed when
TRIM5a forms a complementary super lattice on the viral capsid
and prevents progression to proper uncoating and nuclear entry
(Stremlau et al, 2006; Wu et al, 2006; Ganser-Pornillos et al, 2011);
however, our data cannot formally exclude a role for viral capsid
ubiquitination in the TRIM5a restriction mechanism.
Pertel et al (2011) have postulated that the role of TRIM5a Ub
ligase activity is to stimulate an innate immune response through
the synthesis of unanchored K63-Ub and that this activity is neces-
sary for TRIM5a to restrict viral infection. While we do not find a
requirement for ubiquitination activity in TRIM5a restriction of viral
infection (Figs 1 and 4), our data are compatible with a model in
which TRIM5a synthesizes unanchored polyUb, as we too observed
unanchored polyUb chain synthesis in vitro using recombinant
TRIM5a and either Ube2N/Ube2V2 or Ube2N/Ube2V1 (Fig 5).
However, our findings that: (i) Ube2W was absolutely required for
restriction of viral DNA synthesis, and not infection, and (ii) that
Ube2W causes the K63-Ub to be anchored to TRIM5a itself suggest a
novel mechanism whereby anchored, and not free, K63-Ub is the
necessary signal to trigger downstream effector mechanisms that
result in a block to viral reverse transcription in a proteasome-
dependent manner. We also note that addition of Ube2W to reac-
tions between TRIM5a and Ube2N/Ube2V2 results in a greater
abundance of polyUb, and the produced chains are also shorter
(Supplementary Fig S6). How K63-Ub could underlie proteasome
recruitment remains unclear, although we envisage either a mecha-
nism of Ub chain branching whereby the introduction of additional
Ub chain linkages confers additional function (Nakasone et al,
2013) or via the recruitment of K63-Ub-specific Ub binding domains
that facilitate transfer of ubiquitinated TRIM5a, bound to a viral
capsid, to the proteasome. A potential role for autophagy in TRIM5a
antiviral activity was recently described (Mandell et al, 2014), lend-
ing support to the notion that additional cofactors of TRIM5a remain
to be discovered. Moreover, an alternative autophagic degradation
pathway could explain how K63-Ub induces degradation, with the
effects of proteasome inhibition explained by concomitant distur-
bances in Ub homeostasis.
Mass spectrometry mapping experiments have helped us under-
stand how Ube2W mediates TRIM5a polyUb “anchoring” to
TRIM5a. Analyses of trypsin-digested TRIM5a expressed in cells
revealed that the N-terminus of TRIM5a is quantitatively acetylated
—a modification that blocks N-terminal ubiquitination. In vitro ubiq-
uitination of aN-acetylated-TRIM5a followed by mass spectrometry
analyses demonstrated that Ube2W can catalyze monoubiquitina-
tion of wild-type TRIM5a at multiple lysine residues, predominantly
Lys45 and Lys50 in the TRIM5a RING domain. In lower abundance,
we also detected ubiquitination of lysines 85, 218, 284, and 372.
While aN-acetylated N-terminal peptides were detected in our mass
spectrometry experiments, no N-terminally ubiquitinated peptides
were detected (Supplementary Fig S2). Ube2W is reported to target
protein N-termini preferentially (Scaglione et al, 2013; Tatham et al,
2013; Vittal et al, 2015) and, indeed, we found that Ube2W could
add Ub to the N-terminus when this site was (artificially)
unblocked. Thus, our data show that although Ube2W can target
protein N-termini, it can also target internal lysine residues, as is the
case for native, WT TRIM5arh.
We were able to validate the importance of these six (and two
adjacent) Lys residues in vitro, as TRIM5arh mutated at eight
lysine residues was a poor substrate for Ube2W-mediated mono-
ubiquitination. However, mutation of the corresponding seven
lysine residues in TRIM5ahu did not substantially diminish
TRIM5ahu ubiquitination in cells, suggesting that additional lysine
ª 2015 The Authors The EMBO Journal Vol 34 | No 15 | 2015
Adam J Fletcher et al Ube2W primes TRIM5a autoubiquitination The EMBO Journal
2089
residues can be ubiquitinated, at least when the primary targets are
mutated. Similarly, while TRIM5arh mutated at lysine residues 44,
45, and 50 was also impaired for in vitro ubiquitination with
Ube2W, these mutations did not diminish TRIM5ahu ubiquitination
or restriction activity in cells. One possible explanation for this
discrepancy is that TRIM5a is not itself the functional target of the
K63-Ub that is essential for restriction of viral DNA synthesis.
However, the loss of ubiquitinated TRIM5a species after either E2
enzyme depletion, or Ub K63R expression in cells, correlates with
the loss of restriction of viral DNA synthesis. This observation
supports the notion that TRIM5a itself is the functional target of
ubiquitination (Figs 1, 3 and 4). Another possible explanation is that
we have failed to mutate all of the possible target lysines in TRIM5a.
Our mass spectrometry demonstrated that TRIM5a ubiquitination is
not highly specific. In vitro, the RING domain lysines at positions 45
and 50 are the major targets for autoubiquitination, possibly
because these lysines are the closest to the E2 binding site in the
RING domain. However, conformations adopted by TRIM5a assem-
blies in cells, perhaps aided by additional cofactors, might orientate
the protein such that additional lysines become favored ubiquitina-
tion targets. We observed a hint of Ube2W-catalyzed monoubiquiti-
nated TRIM5arh bearing three or eight lysine–arginine substitutions
in vitro, which was lost on Ube2N/Ube2V2 addition (Fig 7A,
compare lanes 6 and 7), suggesting that in the absence of these
amine groups, TRIM5a might ubiquitinate lysines more distant to
the E2 binding site, albeit less efficiently in our in vitro reactions.
Finally, it is possible that other E3 ligases functionally ubiquitinate
TRIM5a via the E2 enzymes identified here. However, our observa-
tion that TRIM5a is able to autoubiquitinate in vitro using these
enzymes makes TRIM5a itself the most likely E3 candidate for
TRIM5a-dependent restriction.
Although our data do not prove that TRIM5a is the functional
target for Ub-dependent restriction, we favor a model in which
TRIM5a autoubiquitination is necessary for subsequent inhibition of
viral DNA synthesis. In principle, TRIM5a-anchored Ub molecules
offer the advantage that they would presumably remain associated
with the incoming viral capsid and thus could “mark” that capsid
for inactivation. Furthermore, redundancy of target lysines for ubiq-
uitination is consistent with a protein whose effective function
depends on combating rapidly evolving pathogens by evolving
changes in antiviral specificity. Plasticity in the lysines used as ubiq-
uitination targets would reduce the likelihood that TRIM5a
sequence changes would impact its ability to autoubiquitinate.
Redundancy of target lysines may therefore be an advantageous,
evolved property of the TRIM5a protein.
In summary, we have identified a novel series of reactions cata-
lyzed by TRIM5a that result in the anchoring of K63-Ub to TRIM5a
itself. Perturbation of the enzymatic activities involved in the forma-
tion of this modification prevents TRIM5a from restricting retroviral
infection prior to viral reverse transcription. This hitherto unidenti-
fied mechanism appears to lie in the same pathway as proteasome-
dependent disassembly of retroviral capsids. Also, the observed
K63-Ub specificity suggests that a relationship may exist between
TRIM5a restriction of retroviral reverse transcription and stimula-
tion of innate immune signaling cascades. Our study highlights the
value of combining in vitro assays for ubiquitination with cellular
assays for Ub ligase function. The ability to measure TRIM5a ubiq-
uitination activity functionally in cells, using different steps in the
retroviral lifecycle as the readout, makes this an attractive approach
for further studies of TRIM protein-mediated ubiquitination and for
analyzing the contribution of K63-Ub to proteasome recruitment
and innate immune signaling.
Materials and Methods
Cells, viral vectors, chemicals and antibodies
HeLa, TE671, 293T, and CrFK cells were obtained from the Ameri-
can Type Culture Collection and grown in DMEM (Invitrogen) with
10% FCS (Biosera) at 37°C in 5% CO2, (293T in DMEM with 15%
FCS, at 37°C in 10% CO2) and were tested negative for mycoplasma
(Lonza). All media contained 100 U/ml penicillin and 100 lg/ml
streptomycin. VSV-G pseudotyped viral particles were generated by
three-plasmid transfection of 293T with Fugene-6 (Promega), using
1 lg Gag-Pol expression plasmid, 1 lg VSV-G expression plasmid
pMD2.G (GenScript), and 1.5 lg genome vector. Plasmids used
were as follows: pCMVi (MoMLV Gag-Pol), pCIG3-N (N-tropic MLV
Gag-Pol), pCIG3-B (B-tropic MLV Gag-Pol), and pCNCG (MLV-GFP
genome). Human TRIM5a and TRAF6 were cloned from human cell
cDNA and inserted into the retroviral expression vector EXN (a kind
gift from Paul Bieniasz), which express N-terminally HA-tagged
proteins. The HA-tag was deleted by overlap PCR in order to express
C-terminally HA-tagged proteins. TRIM5a mutants were generated
by site-directed mutagenesis (Stratagene). Ubiquitin (Ub) proteins
were expressed from either pMT123 (HA-tagged Ub) or pMT107
(6×His-tagged Ub), which encode a multimeric precursor molecule
comprised of eight consecutive Ub units downstream of the
N-terminal tag (Treier et al, 1994), pcDNA3.1-Kozak-6×His-UbGFP,
or pHR’-SIN-6×His-UbGFP-WT/-K48R/-K63R. In the latter two
constructs, Ub and GFP are post-translationally cleaved producing
Ub monomers and GFP. MG132 (Calbiochem) was used at 2 lg/ml.
Antibodies used in this study were as follows: rat monoclonal to
HA-tag (3F10, Roche, 1:5,000), rabbit polyclonal to Ube2L3 (A-640,
Boston Biochem, 1:1,000), rabbit polyclonal to Ube2N (AB10025,
Millipore, 1:1,000), mouse monoclonal to b-actin (AC-15, Abcam,
1:40,000), mouse monoclonal to His-tag (H8, Millipore, 1:1,000, or
Penta-His 34660, Qiagen, 1:1,000), mouse monoclonal to TRIM5arh
(5D5-1-1, distributed by the NIH AIDS Reagent Repository), mouse
monoclonal to Ub (P4D1, Santa Cruz Biotechnology), and rabbit
monoclonal to Ub, Lys63-specific clone Apu3 (Merck Millipore).
HRP-conjugated secondary antibodies (mouse, rabbit) were from GE
Healthcare and used at 1:5,000. HRP was detected with ECL (GE
Healthcare) or RapidStep ECL (Calbiochem). A complete list of
expression plasmids, antibodies, siRNAs, oligonucleotides, and real-
time qPCR probes used in this study is provided in Supplementary
Table S1.
RNAi-mediated E2 ubiquitin-conjugating enzyme library screen
The siRNA library screen for 38 human E2 Ub-conjugating enzymes
constituted 38 siGENOME SMARTpools (Dharmacon), one pool per
well in a 96-well plate. Pools were resuspended in Optimem and
Oligofectamine. 8 × 103 HeLa cells were added to each pool, with
siRNA concentrations of 30 nM in final volumes of 100 ll. The cells
were incubated at 37°C, washed after 24 h, and incubated for a
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further 24 h. Cells were then infected with N-tropic or B-tropic
MLV-GFP vectors (MOI ~0.2) in a final volume of 200 ll.
shRNA-mediated depletion of Ube2W, Ube2N, and Ube2V2
shRNA-encoding oligonucleotides were designed, annealed, and
ligated into pSIREN Retro Q (Clontech) according to manufacturer’s
instructions (http://www.clontech.com/GB/Support/Online_Tools).
The 19mer target sequences are listed in Supplementary Table S1.
The shRNA sequence designed to deplete Ube2V2 corresponded to
the most effective 19mer target sequence from a screen of four
independent siRNA oligonucleotides. The Ube2N 19mer sequence
was previously described (Duncan et al, 2006). The Ube2W 19mer
sequence targeting the 30UTR was designed according to Clontech
instructions. The Ube2V1 22mer sequence was previously
described (Pertel et al, 2011). TE671 cells were transduced at an
MOI ~1 and selected in 2.5 lg/ml puromycin (Fletcher et al,
2010).
Infectivity and quantitative polymerase chain reaction
(qPCR) assays
105 TE671 cells per well were seeded in 12-well plates and trans-
duced 24 h later (MOI ~0.2) in quadruplicate with RQ1 DNase-
treated (30 U/ml, 2 h, 37°C, in buffer containing 400 mM Tris (pH
8.0), 100 mM MgSO4, and 10 mM CaCl2) N-MLV or B-MLV GFP-
expressing viral vectors, in the presence of 8 lg/ml Polybrene.
Heat-treated viral supernatants (95°C, 5 min) served as controls for
plasmid contamination. 6 h p.i., duplicate wells were washed in
PBS, trypsinized, pelleted, washed again in PBS, pelleted, and stored
at 80°C. Total DNA was extracted using QIAamp DNA Mini Kit
(Qiagen), eluting DNA in 50 ll water. Parallel duplicate wells were
scored for GFP expression by flow cytometry (BD Accuri C6).
Concentration of each DNA sample was quantified using a Nano-
Drop spectrophotometer ND-1000 (Thermo Fisher Scientific).
TaqMan qPCR reactions contained 5 ll of eluted DNA, 300 nM
forward and reverse primers (listed in Supplementary Table S1),
150 nM probe, 20 lg salmon sperm DNA, and 1× TaqMan Universal
Master Mix II (Life Technologies). Standard curves generated from
GFP cDNA plasmids were created in duplicate for each qPCR assay.
Cycle parameters for GFP gene detection were 50°C for 2 min and
95°C for 10 min, followed by 40 cycles of 95°C for 15 s, and 60°C
for 1 min using a Prism 7000 thermocycler (Applied Biosystems).
SYBR Green qPCR assays were used to detect transcript abundance
of E2s, using 1 lM primers as listed in Supplementary Table S1, and
~200 ng cDNA. Cycle parameters were 5 min at 95°C, followed by
40 cycles of 95°C for 10 s and 60°C for 30 s. Standard curves gener-
ated from E2 cDNA plasmids were created in duplicate for each
qPCR assay. The specificity of E2-specific primer pairs was assessed
in control PCRs (Supplementary Fig S1).
cDNA synthesis for quantitation of Ube2W, Ube2V2, and
Ube2V1 depletion
Total RNA was purified using the RNeasy RNA Extraction Kit
according to manufacturer’s instructions (Qiagen). 1 lg RNA was
mixed with 42 ng oligo-dT primer and 0.8 mM dNTPs, heated at
65°C for 5 min, and then chilled on ice. The mixture was then
supplemented to a final concentration of 250 mM Tris (pH 8.3),
375 mM KCl, 15 mM MgCl2, and 10 mM DTT and incubated at
42°C for 2 min. 200 units of SuperScriptTM II reverse transcrip-
tase were then added and the mixture incubated at 42°C for
50 min. The reaction was inactivated by heating at 70°C for
15 min. RNA was degraded by addition of two units E. coli RNase H
(Life Technologies) and incubated at 37°C for 20 min. cDNA was
stored at 20°C.
His-tag affinity purifications
To affinity-purify His-tagged proteins (termed “pull down” purifi-
cations), sub-confluent 10-cm2 dishes of 293T or TE671 cells
were transfected with pcDNA-6×HisTRIM5a (expressing 6×His-
TRIM5a), pMT107 (expressing 6×His-Ub), pMT123 (expressing
HA-Ub), or pcDNA3.1-Kozak-6×His-UbGFP (expressing wild-type,
K48R or K63R 6×His-Ub) with 12 ll Fugene-6 (Roche). 48 h
post-transfection, cells were washed in 10 ml PBS, resuspended
in 1 ml ice-cold PBS, centrifuged, and lysed in 1 ml 6 M GuHCl,
0.1 M Na2HPO4/NaH2PO4 (pH 8), and 10 mM imidazole (pH 8).
Lysates were sonicated for 15 s and rotated for 3 h at room
temperature with 50 ll equilibrated NiNTA agarose (Qiagen).
The agarose matrix was washed twice with 1 ml lysis buffer,
twice with 1 ml 3:1 wash buffer:lysis buffer, once with 1 ml
wash buffer (25 mM Tris, 20 mM imidazole, pH 6.8), resus-
pended in 2× SDS sample buffer supplemented with 300 mM
imidazole to elute bound His-tagged proteins, and 10%
b-mercaptoethanol as a reducing agent, and heated for 10 min at
95°C prior to SDS–PAGE.
E. coli expression vectors
Genes encoding the following E2 enzymes: Ube2B, Ube2C,
Ube2D3, Ube2H, Ube2L3, Ube2N, Ube2V1, Ube2V2, and Ube2W,
were amplified in PCRs to create DNA fragments that contained
the E2 genes flanked by NheI and XhoI restriction sites (see
Supplementary Table S1 for details). These DNA fragments were
ligated into a pET11 vector modified to express proteins in frame
with an N-terminal 6×His tag followed by a precision protease
cleavage site. The resulting vectors were used to express recombi-
nant E2 enzymes in E. coli and are designated pET11His-Ube2B
(WISP11-266), pET11His-Ube2C (WISP11-267), pET11His-Ube2D3
(WISP14-34), pET11His-Ube2H (WISP11-270), pET11His-Ube2L3
(WISP14-35), pET11His-Ube2N (WISP11-269), pET11His-Ube2V1
(WISP14-36), pET11His-Ube2V2 (WISP11-272), and pET11His-
Ube2W (WISP14-37).
The plasmid for expression of Ub, pET15b-Ubiquitin (WISP11-
276), was a generous gift from Rachel Klevit (University of Wash-
ington). This plasmid was used as a template for site-directed muta-
genesis to create vectors that expressed Ub proteins with each
possible single Lys to Arg mutation as well as a Ub protein with all
seven Lys residues mutated to Arg. These plasmids are designated:
pET15b-Ub K6R (WISP11-277), pET15b-Ub K11R (WISP14-38),
pET15b-Ub K27R (WISP14-39), pET15b-Ub K29R (WISP14-40),
pET15b-Ub K33R (WISP14-41), pET15b-Ub K48R (WISP11-278),
pET15b-Ub K63R (WISP11-279), and pET15b-Ub K0 (WISP14-42).
The plasmid for expression of human UBA1, pET21-UBA1, was a
generous gift from Cynthia Wolberger (Johns Hopkins University).
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Expression and purification of recombinant proteins
Recombinant Ub, UBA1, and E2 proteins were expressed in Rosetta
(DE3) pLysS bacteria (EMD Millipore) grown in LB media and were
purified to homogeneity. Briefly, human UBA1, Ube2B, Ube2C,
Ube2D3, Ube2H, Ube2L3, Ube2N, Ube2V1, Ube2V2, and Ube2W
were purified by affinity chromatography on Ni-NTA agarose
(Qiagen) and eluted with 0.5 M imidazole in buffer containing
50 mM HEPES (pH 7.0) and 300 mM NaCl. The eluted E2 proteins
were treated further with precision protease, and the solutions were
incubated at 4°C overnight to remove the 6×His tags (leaving non-
native Gly-Pro dipeptides at the N-termini). The UBA1 and E2
enzymes were then purified further by size exclusion chromato-
graphy in 50 mM HEPES pH 7.2 and 100 mM NaCl. Ub was purified
as described previously (Pickart & Raasi, 2005).
Pure rhesus TRIM5a (TRIM5arh) protein was a generous gift from
Vish Chandrasekaran (Li et al, manuscript in preparation). Briefly,
Flag-One-Strep (FOS)-tagged TRIM5arh was expressed from a
baculoviral vector in SF21 insect cells, purified by affinity chromato-
graphy on streptactin agarose, treated with precision protease to
remove the FOS tag, and then purified to homogeneity by anion and
gel filtration chromatography. The protein corresponds to wild-type
TRIM5arh except that it has a non-native LEVLFQ peptide at the
C-terminus.
Ubiquitination activity assays
TRIM5arh ubiquitination assays were carried out in 30 ll reaction
mixtures that contained 0.4 lM TRIM5arh, 0.4 lM concentrations of
the specified E2 enzyme(s), 10 lM Ub, and 0.2 lM UBA1. ATP and
MgCl2 were added to final concentrations of 5 and 10 mM, respec-
tively, and the reaction mixtures were incubated for 30 min at 37°C.
TRIM5arh reaction products were analyzed by 4–15% SDS–PAGE
gradient gels (Bio-Rad) and Western blotting. For immunoblotting,
proteins were separated by SDS–PAGE, transferred to nitrocellulose
membranes (Bio-Rad) in Tris-glycine–10% methanol buffer, blocked
in 2% milk–Tris-buffered saline (20 min), and incubated (16 h,
4°C) with the murine monoclonal anti-TRIM5arh antibody (5D5-1-1)
(1:1,000 dilution into 2% non-fat milk–Tris-buffered saline plus
0.1% Tween 20), followed by incubation with an Alexa 680 nm-
labeled secondary anti-mouse antibody (Molecular Probes; 1:10,000
dilution). Blots were visualized by using an Odyssey infrared
imaging system (Li-Cor, Inc.)
Mass spectrometry
ESI/MS analysis of TRIM5a as an intact protein
Protein samples were purified using a C18 ZiptipTM (Millipore) to
remove salts and other small molecule contaminants. The protein
was loaded onto a ZiptipTM in 5% acetonitrile and then washed with
200–500 ll of 5% acetonitrile with 1% formic acid. Proteins were
eluted from the ZiptipTM and collected in a pre-rinsed micro-
centrifuge tube with three consecutive 0.75-ll aliquots of 60%
acetonitrile with 1% formic acid, then one 1-ll aliquot of 98%
acetonitrile with 2% formic acid was added, and then 1 ll of 5%
formic acid was added prior to ESI/MS analysis.
ESI/MS analysis of intact TRIM5a was performed using a Q-ToF-2
mass spectrometer (Waters). 3 ll of eluent was infused into the
instrument with using a nanochip autosampler (Triversa Nano-
MateTM, Advion) with nanoflow static infusion at a rate of ~100 nl/min.
Electrospray ionization was used in the positive-ion mode, but
with the ion-source spray voltage of the Q-ToF-2 instrument set to
zero. Ionization spray voltage was applied with the Triversa Nano-
Mate at 1.51 kV at the nozzle of the nanochip device. Spectra were
acquired with a cone voltage of 45 eV, and the instrument was
scanned from 600 to 1,400 m/z in 2 s. Scans were accumulated for
about 1 min. Spectra were combined, and multiply-charged molec-
ular ions were deconvoluted into a molecular-mass spectrum
processed into the average-isotope neutral molecular weight using
MaxEntTM software (Waters).
LC/MS/MS analysis of TRIM5a and ubiquitin
TRIM5a was analyzed by LC/MS/MS following tryptic digest of gel
bands and also from solution samples. Peptides were analyzed using
a nano-LC/MS/MS system comprised of a nano-LC pump (2D-ultra,
Eksigent) and a LTQ-FT mass spectrometer (ThermoElectron Corpo-
ration, San Jose, CA). The LTQ-FT is a hybrid mass spectrometer in
which the linear-ion trap was used for MS/MS sequencing of
peptides (collision-induced dissociation (CID) fragmentation with
helium collision gas), and the Fourier transform ion-cyclotron reso-
nance (FT-ICR) part of the instrument was used to acquire MS data
with high mass accuracy and high resolution. All TRIM5a peptides
identified were within 3 ppm mass error compared to theoretical
values, but most peptides were within 2 ppm mass error. The LTQ-
FT was equipped with a nanospray ion source (ThermoElectron) at
2.3-kV spray voltage. The LTQ-FT mass spectrometer was operated
in data-dependent acquisition mode controlled by Xcalibur 1.4 soft-
ware, in which the “top 10” most intense peaks observed in an FT
primary scan (i.e., MS survey spectrum) are subsequently trapped
for MS/MS fragmentation and analysis in the LTQ linear-ion trap
part of the instrument. Spectra in the FT-ICR were acquired from
m/z 350 to 1,400 at 50,000 resolution at a rate of about three full
scans per second. The LTQ linear-ion trap was operated with the
following parameters: precursor activation time 30 ms and activa-
tion Q at 0.25; collision energy was set at 35%; dynamic exclusion
width was set at low mass of 0.1 Da and high mass at 2.1 Da with
one repeat count and duration of 10 s.
Nano-LC Approximately 5–20 fmoles of tryptic digest was dissolved
in 5% acetonitrile with 0.1% formic acid and injected onto a C18
nanobore LC column for nano-LC/MS/MS and identification of
peptides. The nanobore column was packed and assembled home-
made [C18 (Atlantis, Waters Corp); 3-lm particle; column: 75 lm
ID × 100 mm length; unpacked column from New Objective]. A
linear gradient LC profile was used to separate and elute peptides
with a constant total flow rate of 350 nl/min. The gradient consisted
of 5–80% solvent B in 78 min (solvent B: 80% acetonitrile with
0.1% formic acid; solvent A: 5% acetonitrile with 0.1% formic
acid).
In-gel digest of proteins SDS–PAGE gel slices were destained in
50% methanol, sliced into small pieces, and dehydrated in aceto-
nitrile, and then the acetonitrile removed prior to digestion. The
gel pieces were digested with TPCK-modified sequencing grade
trypsin (Promega). 10 ll of trypsin (i.e. 20 ng/ll in 50 mM
ammonium bicarbonate) was added and 20 more ll of 50 mM
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ammonium bicarbonate was added to the gel pieces. Digestion
was allowed to continue for 2 h (at 37°C), and then two more
aliquots of 20 ll of trypsin was added at 2-h intervals and then
allow to continue digesting overnight. This relatively aggressive
digest protocol was needed to improve the yield of peptides from
Ub and TRIM5a proteins. The digestion was quenched by the
addition of 20 ll 1% formic acid. This solution was allowed to
stand and peptides that dissolved in the 1% formic solution were
extracted and collected. Further extraction of peptides from the
gel material was performed twice by the addition of 50% acetoni-
trile with 1% formic acid and sonicated at 37°C for 20 min, and
these solutions were also collected and combined. A final
complete dehydration of the gel pieces was accomplished by
addition of 20 ll of 100% acetonitrile and incubation at 37°C for
20 min. The combined supernatant solutions of extracted peptides
were combined and dried in a vacuum centrifuge (Speed-Vac).
The peptides were reconstituted in 100 ll of 5% acetonitrile with
0.1% formic acid for LC/MS/MS analysis. After further dilution,
2% of the total digest volume was injected on the nano-LC
column for LC/MS/MS analysis in a 5 ll volume.
Digests of proteins in solution A 15-ll aliquot of ~1–10 pmoles of
protein in solution was digested with trypsin. Proteins in solution
were digested with TPCK-modified trypsin (Promega) following the
trypsin protocol outlined above. 6% of the total digest volume was
injected on the nano-LC column for LC/MS/MS analysis in a 5 ll
volume. All solution samples within a set of samples were analyzed
identically and in a quantitative manner (i.e. sample volume, digest
protocol, injection amount, and LC/MS/MS analysis).
Protein and peptide identifications
Database searches All identified proteins and peptides from protein
digest samples were assigned from protein database searches of the
LC/MS/MS data, using in-house processing with MASCOT search
engine (in-house licensed, ver. 2.2.7, Matrix Science, Inc.). Mascot
searching was performed from an in-house computer, in which
NCBI and “custom” protein databases were searched. Searches were
also performed using Proteome Discoverer (Thermo, version 1.4), in
which Sequest and Mascot searched were conducted. Peptides were
searched assuming the following criteria:
1 Trypsin-specific cut sites, allowing for two missed cleavages.
2 Accurate mass measurement of peptide molecular ions by FTMS
with search window 5 ppm (but peptides typically will have
< 2 ppm mass error). Molecular ions with +1, +2, or +3 charge
states were considered.
3 Peptide sequence information from MS/MS; CID fragmentation
of the parent ion of each peptide was obtained in the linear-ion
trap region of the LTQ-FT instrument. 0.5 Da mass error toler-
ance was allowed for peptide fragment ion masses in the search
(but MS/MS fragment ions typically have errors < 0.3 Da).
4 Mass data peak lists for the Mascot searches were generated
using Sequest in Qual Browser software (Bioworks Browser 3.2,
Excalibur, Thermo) or with Proteome Discoverer.
5 Peptide modifications were included in the search as variables
(e.g. oxidation on methionine, histidine, or tryptophan; ubiquiti-
nation on lysine and N-terminus amino acid; acetylation on
N-terminus amino acid).
6 Mascot threshold cutoffs for acceptable identified peptides
have MASCOT scores > 20, mass errors < 3 ppm, and expect
values < 1.
Supplementary information for this article is available online:
http://emboj.embopress.org
Acknowledgements
We thank Vish Chandrasekaran for the generous gift of pure recombinant
TRIM5arh proteins, and for helpful discussions. This work was funded by NIH
Grant P50 GM 082545-07 to WIS, a Wellcome Trust Senior Biomedical
Research Fellowship 090940 to GJT, the European Research Council under the
European Union’s Seventh Framework Programme (FP7/2007-2013) / ERC
grant agreement number 339223, the Medical Research Council and the
National Institute for Health Research University College London Hospitals
Biomedical Research Centre.
Author contributions
AJF, DEC, WIS, and GJT conceived the study, and AJF performed the
experiments described in Figs 1–4 and Supplementary Figs S1, S5B–D and
S8. DEC performed and WIS and DEC directed the experiments described in
Figs 5–7 and Supplementary Figs S2–S4, S5A, S6 and S7. CN and DEC
performed and analyzed the biochemical and mass spectrometry
experiments described in Table 1 and Supplementary Figs S2, S3 and S7.
PJL provided the E2 RNAi library and protocol. CPT and TS contributed
reagents and experimental data. AJF, DEC, WIS, and GJT wrote the
manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Alpi AF, Pace PE, Babu MM, Patel KJ (2008) Mechanistic insight into site-
restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI.
Mol Cell 32: 767 – 777
Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, Hope TJ (2006)
Proteasome inhibition reveals that a functional preintegration complex
intermediate can be generated during restriction by diverse TRIM5
proteins. J Virol 80: 9754 – 9760
Arimoto K, Funami K, Saeki Y, Tanaka K, Okawa K, Takeuchi O, Akira S,
Murakami Y, Shimotohno K (2010) Polyubiquitin conjugation to NEMO by
triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc Natl
Acad Sci USA 107: 15856 – 15861
Besnier C, Ylinen L, Strange B, Lister A, Takeuchi Y, Goff SP, Towers GJ (2003)
Characterization of murine leukemia virus restriction in mammals. J Virol
77: 13403 – 13406
Bienvenut WV, Sumpton D, Martinez A, Lilla S, Espagne C, Meinnel T, Giglione
C (2012) Comparative large scale characterization of plant versus
mammal proteins reveals similar and idiosyncratic N-alpha-acetylation
features. Mol Cell Proteomics 11: M111 –M015131
Biris N, Yang Y, Taylor AB, Tomashevski A, Guo M, Hart PJ, Diaz-Griffero F,
Ivanov DN (2012) Structure of the rhesus monkey TRIM5alpha PRYSPRY
domain, the HIV capsid recognition module. Proc Natl Acad Sci USA 109:
13278 – 13283
Black LR, Aiken C (2010) TRIM5alpha disrupts the structure of assembled HIV-
1 capsid complexes in vitro. J Virol 84: 6564 – 6569
ª 2015 The Authors The EMBO Journal Vol 34 | No 15 | 2015
Adam J Fletcher et al Ube2W primes TRIM5a autoubiquitination The EMBO Journal
2093
Campbell EM, Perez O, Anderson JL, Hope TJ (2008) Visualization of a
proteasome-independent intermediate during restriction of HIV-1 by
rhesus TRIM5alpha. J Cell Biol 180: 549 – 561
Christensen DE, Brzovic PS, Klevit RE (2007) E2-BRCA1 RING interactions
dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat
Struct Mol Biol 14: 941 – 948
Danielson CM, Cianci GC, Hope TJ (2012) Recruitment and dynamics of
proteasome association with rhTRIM5alpha cytoplasmic complexes during
HIV-1 infection. Traffic 13: 1206 – 1217
Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, Sodroski J
(2006) Rapid turnover and polyubiquitylation of the retroviral restriction
factor TRIM5. Virology 349: 300 – 315
Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, Lienlaf M,
Yokoyama S, Sodroski J (2009) A B-box 2 surface patch important for
TRIM5alpha self-association, capsid binding avidity, and retrovirus
restriction. J Virol 83: 10737 – 10751
Duncan LM, Piper S, Dodd RB, Saville MK, Sanderson CM, Luzio JP, Lehner PJ
(2006) Lysine-63-linked ubiquitination is required for endolysosomal
degradation of class I molecules. EMBO J 25: 1635 – 1645
Fletcher AJ, Hue S, Schaller T, Pillay D, Towers GJ (2010) Hare TRIM5alpha
restricts divergent retroviruses and exhibits significant sequence
variation from closely related lagomorpha TRIM5 genes. J Virol 84:
12463 – 12468
Flick K, Ouni I, Wohlschlegel JA, Capati C, McDonald WH, Yates JR, Kaiser P
(2004) Proteolysis-independent regulation of the transcription factor Met4
by a single Lys 48-linked ubiquitin chain. Nat Cell Biol 6: 634 – 641
Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen
Z, Inoue S, Jung JU (2007) TRIM25 RING-finger E3 ubiquitin ligase is
essential for RIG-I-mediated antiviral activity. Nature 446: 916 – 920
Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist
WI, Yeager M (2011) Hexagonal assembly of a restricting TRIM5alpha
protein. Proc Natl Acad Sci USA 108: 534 – 539
Goldstone DC, Walker PA, Calder LJ, Coombs PJ, Kirkpatrick J, Ball NJ, Hilditch
L, Yap MW, Rosenthal PB, Stoye JP, Taylor IA (2014) Structural studies of
postentry restriction factors reveal antiparallel dimers that enable avid
binding to the HIV-1 capsid lattice. Proc Natl Acad Sci USA 111:
9609 – 9614
Hofmann RM, Pickart CM (1999) Noncanonical MMS2-encoded ubiquitin-
conjugating enzyme functions in assembly of novel polyubiquitin chains
for DNA repair. Cell 96: 645 – 653
Keckesova Z, Ylinen LM, Towers GJ (2004) The human and African green
monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction
factor activities. Proc Natl Acad Sci USA 101: 10780 – 10785
Kim J, Tipper C, Sodroski J (2011) Role of TRIM5alpha RING domain E3
ubiquitin ligase activity in capsid disassembly, reverse transcription
blockade, and restriction of simian immunodeficiency virus. J Virol 85:
8116 – 8132
Kutluay SB, Perez-Caballero D, Bieniasz PD (2013) Fates of retroviral core
components during unrestricted and TRIM5-restricted infection. PLoS
Pathog 9: e1003214
Lukic Z, Hausmann S, Sebastian S, Rucci J, Sastri J, Robia SL, Luban J,
Campbell EM (2011) TRIM5alpha associates with proteasomal subunits in
cells while in complex with HIV-1 virions. Retrovirology 8: 93
Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC
(2010) Antibodies mediate intracellular immunity through tripartite motif-
containing 21 (TRIM21). Proc Natl Acad Sci USA 107: 19985 – 19990
Mandell MA, Jain A, Arko-Mensah J, Chauhan S, Kimura T, Dinkins C, Silvestri
G, Munch J, Kirchhoff F, Simonsen A, Wei Y, Levine B, Johansen T, Deretic
V (2014) TRIM proteins regulate autophagy and can target autophagic
substrates by direct recognition. Dev Cell 30: 394 – 409
Markson G, Kiel C, Hyde R, Brown S, Charalabous P, Bremm A, Semple J,
Woodsmith J, Duley S, Salehi-Ashtiani K, Vidal M, Komander D, Serrano L,
Lehner P, Sanderson CM (2009) Analysis of the human E2 ubiquitin
conjugating enzyme protein interaction network. Genome Res 19:
1905 – 1911
McEwan WA, Schaller T, Ylinen LM, Hosie MJ, Towers GJ, Willett BJ (2009)
Truncation of TRIM5 in the Feliformia explains the absence of retroviral
restriction in cells of the domestic cat. J Virol 83: 8270 – 8275
McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC (2013)
Intracellular antibody-bound pathogens stimulate immune signaling via
the Fc receptor TRIM21. Nat Immunol 14: 327 – 336
McKenna S, Moraes T, Pastushok L, Ptak C, Xiao W, Spyracopoulos L, Ellison
MJ (2003) An NMR-based model of the ubiquitin-bound human ubiquitin
conjugation complex Mms2.Ubc13. The structural basis for lysine 63 chain
catalysis. J Biol Chem 278: 13151 – 13158
McNab FW, Rajsbaum R, Stoye JP, O’Garra A (2011) Tripartite-motif proteins
and innate immune regulation. Curr Opin Immunol 23: 46 – 56
Nakasone MA, Livnat-Levanon N, Glickman MH, Cohen RE, Fushman D (2013)
Mixed-linkage ubiquitin chains send mixed messages. Structure 21:
727 – 740
Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction
and antiviral defence. Nat Rev Microbiol 3: 799 – 808
Peng J, Schwartz D, Elias JE, Thoreen CC, Cheng D, Marsischky G, Roelofs J,
Finley D, Gygi SP (2003) A proteomics approach to understanding protein
ubiquitination. Nat Biotechnol 21: 921 – 926
Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J (2004)
TRIM5alpha mediates the postentry block to N-tropic murine leukemia
viruses in human cells. Proc Natl Acad Sci USA 101: 11827 – 11832
Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, Reinhard C,
Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambio-De-
Castillia C, Mothes W, Pizzato M, Grutter MG, Luban J (2011) TRIM5 is
an innate immune sensor for the retrovirus capsid lattice. Nature 472:
361 – 365
Pickart CM, Raasi S (2005) Controlled synthesis of polyubiquitin chains.
Methods Enzymol 399: 21 – 36
Polevoda B, Sherman F (2003) N-terminal acetyltransferases and sequence
requirements for N-terminal acetylation of eukaryotic proteins. J Mol Biol
325: 595 – 622
Rold CJ, Aiken C (2008) Proteasomal degradation of TRIM5alpha during
retrovirus restriction. PLoS Pathog 4: e1000074
Scaglione KM, Zavodszky E, Todi SV, Patury S, Xu P, Rodriguez-Lebron E,
Fischer S, Konen J, Djarmati A, Peng J, Gestwicki JE, Paulson HL (2011)
Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol
Cell 43: 599 – 612
Scaglione KM, Basrur V, Ashraf NS, Konen JR, Elenitoba-Johnson KS, Todi SV,
Paulson HL (2013) The ubiquitin-conjugating enzyme (E2) Ube2w
ubiquitinates the N terminus of substrates. J Biol Chem 288:
18784 – 18788
Sebastian S, Grutter C, Strambio de Castillia C, Pertel T, Olivari S, Grutter MG,
Luban J (2009) An invariant surface patch on the TRIM5alpha PRYSPRY
domain is required for retroviral restriction but dispensable for capsid
binding. J Virol 83: 3365 – 3373
Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, Wu X, Tao Z, Li Z, Cai X, Sun S, Xiang
C, Sun B (2008) TRIM30 alpha negatively regulates TLR-mediated NF-
kappa B activation by targeting TAB2 and TAB3 for degradation. Nat
Immunol 9: 369 – 377
The EMBO Journal Vol 34 | No 15 | 2015 ª 2015 The Authors
The EMBO Journal Ube2W primes TRIM5a autoubiquitination Adam J Fletcher et al
2094
Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J (2004)
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in
Old World monkeys. Nature 427: 848 – 853
Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F,
Anderson DJ, Sundquist WI, Sodroski J (2006) Specific recognition and
accelerated uncoating of retroviral capsids by the TRIM5alpha restriction
factor. Proc Natl Acad Sci USA 103: 5514 – 5519
Tatham MH, Plechanovova A, Jaffray EG, Salmen H, Hay RT (2013) Ube2W
conjugates ubiquitin to alpha-amino groups of protein N-termini. Biochem
J 453: 137 – 145
Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP, Danos O (2000) A
conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad
Sci USA 97: 12295 – 12299
Towers GJ (2007) The control of viral infection by tripartite motif proteins
and cyclophilin A. Retrovirology 4: 40
Treier M, Staszewski LM, Bohmann D (1994) Ubiquitin-dependent c-Jun
degradation in vivo is mediated by the delta domain. Cell 78: 787 – 798
Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, Kawai T, Akira S
(2010) The ubiquitin ligase TRIM56 regulates innate immune responses to
intracellular double-stranded DNA. Immunity 33: 765 – 776
Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, Mothes W (2013)
TRIM protein-mediated regulation of inflammatory and innate immune
signaling and its association with antiretroviral activity. J Virol 87:
257 – 272
Van Damme P, Arnesen T, Gevaert K (2011) Protein alpha-N-acetylation
studied by N-terminomics. FEBS J 278: 3822 – 3834
VanDemark AP, Hofmann RM, Tsui C, Pickart CM, Wolberger C (2001)
Molecular insights into polyubiquitin chain assembly: crystal structure of
the Mms2/Ubc13 heterodimer. Cell 105: 711 – 720
Versteeg GA, Rajsbaum R, Sanchez-Aparicio MT, Maestre AM, Valdiviezo J,
Shi M, Inn KS, Fernandez-Sesma A, Jung J, Garcia-Sastre A (2013) The
E3-ligase TRIM family of proteins regulates signaling pathways
triggered by innate immune pattern-recognition receptors. Immunity 38:
384 – 398
Vittal V, Shi L, Wenzel DM, Scaglione KM, Duncan ED, Basrur V, Elenitoba-
Johnson KS, Baker D, Paulson HL, Brzovic PS, Klevit RE (2015) Intrinsic
disorder drives N-terminal ubiquitination by Ube2w. Nat Chem Biol 11:
83 – 89
Wang J, Liu B, Wang N, Lee YM, Liu C, Li K (2011) TRIM56 is a virus- and
interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. J
Virol 85: 3733 – 3745
Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ (2006)
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1
reverse transcription and infection. Proc Natl Acad Sci USA 103:
7465 – 7470
Wu F, Kirmaier A, Goeken R, Ourmanov I, Hall L, Morgan JS, Matsuda K,
Buckler-White A, Tomioka K, Plishka R, Whitted S, Johnson W, Hirsch VM
(2013) TRIM5 alpha drives SIVsmm evolution in rhesus macaques. PLoS
Pathog 9: e1003577
Wu F, Ourmanov I, Riddick N, Matsuda K, Whitted S, Plishka RJ,
Buckler-White A, Starost MF, Hirsch VM (2015) TRIM5alpha restriction
affects clinical outcome and disease progression in simian
immunodeficiency virus-infected rhesus macaques. J Virol 89:
2233 – 2240
Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ (2009)
Direct activation of protein kinases by unanchored polyubiquitin chains.
Nature 461: 114 – 119
Yamauchi K, Wada K, Tanji K, Tanaka M, Kamitani T (2008) Ubiquitination of
E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J 275:
1540 – 1555
Yap MW, Nisole S, Lynch C, Stoye JP (2004) Trim5alpha protein restricts both
HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 101:
10786 – 10791
Zhang Y, Zhou X, Zhao L, Li C, Zhu H, Xu L, Shan L, Liao X, Guo Z, Huang P
(2011) UBE2W interacts with FANCL and regulates the
monoubiquitination of Fanconi anemia protein FANCD2. Mol Cells 31:
113 – 122
Zhao G, Ke D, Vu T, Ahn J, Shah VB, Yang R, Aiken C, Charlton LM,
Gronenborn AM, Zhang P (2011) Rhesus TRIM5alpha disrupts the HIV-1
capsid at the inter-hexamer interfaces. PLoS Pathog 7: e1002009
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2015 The Authors The EMBO Journal Vol 34 | No 15 | 2015
Adam J Fletcher et al Ube2W primes TRIM5a autoubiquitination The EMBO Journal
2095
